Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Non-Current Deffered Revenue (2016 - 2022)

Protalix BioTherapeutics has reported Non-Current Deffered Revenue over the past 13 years, most recently at $5.9 million for Q2 2022.

  • Quarterly results put Non-Current Deffered Revenue at $5.9 million for Q2 2022, up 364.54% from a year ago — trailing twelve months through Jun 2022 was $5.9 million (up 364.54% YoY), and the annual figure for FY2021 was $11.8 million, up 587.06%.
  • Non-Current Deffered Revenue for Q2 2022 was $5.9 million at Protalix BioTherapeutics, roughly flat from $5.9 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for PLX hit a ceiling of $34.9 million in Q2 2019 and a floor of $858000.0 in Q1 2021.
  • Median Non-Current Deffered Revenue over the past 5 years was $9.5 million (2020), compared with a mean of $15.0 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: crashed 94.64% in 2020 and later skyrocketed 587.06% in 2021.
  • Protalix BioTherapeutics' Non-Current Deffered Revenue stood at $33.0 million in 2018, then plummeted by 48.59% to $17.0 million in 2019, then tumbled by 89.89% to $1.7 million in 2020, then skyrocketed by 587.06% to $11.8 million in 2021, then crashed by 50.0% to $5.9 million in 2022.
  • The last three reported values for Non-Current Deffered Revenue were $5.9 million (Q2 2022), $5.9 million (Q1 2022), and $11.8 million (Q4 2021) per Business Quant data.